Focal Ablative STereotactic RAdiosurgery for Cancers of the Kidney - a Phase II Clinical Trial

Surgery is the standard treatment for primary kidney cancer, however, in some cases surgery is either not possible or other health problems make surgery high risk. This study involves a relatively new, highly precise multidirectional radiotherapy technique called Stereotactic Ablative Body Radiotherapy (SABR) and all participants will receive this radiotherapy technique. The aim of the study is to test the ability of this technique to control the cancer within the kidney for those people where surgery is not an option, as well as to examine the side effects of the treatment, including how it may affect your kidney’s function.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Collaborating Groups

Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

Final Accrual

71

Closing Date of Accrual

2nd March 2020

Trial Chairperson

A/Prof Shankar Siva, Peter MacCallum Cancer Centre, VIC

Trial Contact

FASTRACKII@trog.com.au

Clinical Trial Registration

Related Post

11 June, 2025

Trial Could Prove a Game-Changer for Treating High-Risk Skin Cancer

LATEST NEWS: 11 JUNE 2025 New findings from a

Grant for PRIME-Lung trial
10 June, 2025

MRFF $1.5m grant for TROG-sponsored trial of new approach in lung cancer

LATEST NEWS: 10 JUNE 2025 A trial of a